Advertisement
Canada markets open in 6 hours 43 minutes

  • S&P/TSX

    21,656.05
    +13.18 (+0.06%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • CAD/USD

    0.7276
    +0.0012 (+0.17%)
     

  • CRUDE OIL

    82.73
    +0.04 (+0.05%)
     

  • Bitcoin CAD

    83,732.00
    -4,209.01 (-4.79%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,392.90
    +4.50 (+0.19%)
     

  • RUSSELL 2000

    1,947.95
    -19.53 (-0.99%)
     

  • 10-Yr Bond

    4.5850
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,756.25
    +97.75 (+0.55%)
     

  • VOLATILITY

    18.21
    -0.19 (-1.03%)
     

  • FTSE

    7,847.99
    +27.63 (+0.35%)
     

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • CAD/EUR

    0.6804
    +0.0002 (+0.03%)
     

NVAX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Novavax, Inc.

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - November 28, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Novavax, Inc. ("Novavax") (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/novavax-inc-loss-submission-form-2?prid=21608&wire=5

Allegations against NVAX include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) Novavax overstated its manufacturing capabilities and downplayed manufacturing issues that would impact its approval timeline for NVX-CoV2373, a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 coronavirus; (ii) as a result, Novavax was unlikely to meet its anticipated Emergency Use Authorization regulatory timelines for NVX-CoV2373; (iii) accordingly, the Company overstated the regulatory and commercial prospects for NVX-CoV2373; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

ADVERTISEMENT

If you suffered a loss in Novavax you have until January 11, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/105422